Home J!Research Publications Novo

Role of recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery

Research Area: Uncategorized Year: 2011
Type of Publication: Article
  • Koncar, Igor
  • Davidovic, L
  • Savic, N
  • Sindjelic, R
  • Ilic, N
  • Dragas, M
Journal: Journal of vascular surgery Volume: 53
Number: 4 Pages: 1032-37
Month: April
ISSN: 0741-5214
Journal's impact factor: 3
Background: Most recent publications have shown that the recombinant form of activated factor VII (rFVIIa; NovoSeven, Novo Nordisk A/S, Bagsværd, Denmark) induces excellent hemostasis in patients with severe intractable bleeding caused by trauma and major surgery. The purpose of this study was to determine the influence of rFVIIa on the treatment of intractable perioperative bleeding in vascular surgery when conventional hemostatic measures are inadequate. Materials and Methods: There were two groups of patients: the NovoSeven group (group N), 10 patients with ruptured abdominal aortic aneurysms (RAAAs) and 14 patients operated on due to thoracoabdominal aortic aneurysms (TAAAs); the control group (group C), 14 patients with RAAAs and 17 patients with TAAAs. All patients suffered intractable hemorrhage refractory to conventional hemostatic measures, while patients from group N were additionally treated with rFVIIa. Results: Postoperative blood loss was significantly lower in group N treated with rFVII (P
Full text: RFVII jvs.pdf